论文部分内容阅读
目的探讨口服吉非替尼联合三维适形放疗治疗表皮生长因子受体(EGFR)突变型Ⅲ期T 1~3N 2~3肺腺癌患者的临床效果。方法 2008年9月至2011年9月间在泰州市人民医院收治的78例EGFR突变型Ⅲ期T 1~3N 2~3肺腺癌患者中,按照随机数表法随机分为观察组和对照组,每组各39例。观察组患者采用吉非替尼联合三维适形放疗治疗;对照组患者给予吉非替尼治疗。观察并比较两组患者的完全缓解率、部分缓解率、中位生存期、无进展生存期和总生存期。结果观察组患者的完全缓解率显著高于对照组,中位生存期和无进展生存期显著长于对照组,差异均有统计学意义(均P<0.05);观察组患者的总生存期差异无统计学意义(P>0.05);观察组患者的不良反应发生率低于对照组(P<0.05),但所有患者均可耐受。结论对EGFR突变型Ⅲ期T 1~3N 2~3肺腺癌患者予以口服吉非替尼联合三维适应放疗治疗,可以获得良好的效果,值得临床推广。
Objective To investigate the clinical efficacy of oral gefitinib combined with three-dimensional conformal radiotherapy in the treatment of epidermal growth factor receptor (EGFR) mutant stage Ⅲ T 1 ~ 3N 2 ~ 3 lung adenocarcinoma. Methods From September 2008 to September 2011, 78 patients with stage Ⅲ T 1 ~ 3N 2 ~ 3 lung adenocarcinoma with EGFR mutation in Taizhou People’s Hospital were randomly divided into observation group and control group according to random number table method Group, 39 cases in each group. Patients in the observation group were treated with gefitinib in combination with three-dimensional conformal radiotherapy; patients in the control group were treated with gefitinib. The complete remission rate, partial remission rate, median survival, progression-free survival and overall survival were observed and compared between the two groups. Results The complete remission rate of the observation group was significantly higher than that of the control group, and the median survival and progression-free survival were significantly longer than those of the control group (all P <0.05). There was no difference in the overall survival between the observation group and the control group The incidence of adverse reactions in the observation group was lower than that in the control group (P <0.05), but all the patients were tolerant. Conclusions Gefitinib combined with three-dimensional radiotherapy for EGFR mutant stage Ⅲ T 1 ~ 3N 2 ~ 3 lung adenocarcinoma patients can achieve good results and is worthy of clinical promotion.